PVLA today
$153.18-$10.76 (-6.56%)close Nov 12, 2026Trend
DailyUptrend (confirmed)
4 hourStrong Bearish
1 hourLeaning Bearish
15 minStrong Bearish
5 minBearish
Daily trend turns down below $118.22
Key levels
Resistance$179.95
Resistance$156.82
Support$141.98
Support$131.20
Latest news & SEC filings
SEC FilingPalvella Therapeutics, Inc. filed an insider trading report (Form 4)
AnalystCanaccord Genuity keeps Buy rating on Palvella Therapeutics, lifts price target
AnalystCanaccord Genuity keeps Buy rating on Palvella Therapeutics, lifts target to $243
AnalystOppenheimer lifts its target price for Palvella Therapeutics shares to $232
All PVLA news →About Palvella Therapeutics
Palvella Therapeutics is a clinical-stage biopharmaceutical company working on topical medicines for uncommon dermatologic conditions and vascular abnormalities that currently have no approved treatment options. Its main candidate, QTORIN rapamycin, is being tested in microcystic lymphatic malformations, cutaneous venous malformations, and angiokeratomas, while QTORIN pitavastatin is in development for disseminated superficial actinic porokeratosis. The company's QTORIN technology aims to deliver drugs into deeper skin layers, and it also runs earlier research programs. It operates in the United States, serving patients and clinicians at vascular anomaly centers.
Based on the company's 10-K filed Mar 31, 2026.
Nasdaq · Healthcare
PALVELLA THERAPEUTICS, INC. (PVLA)
What Is the Price Target for PVLA?
SEPT Low Target
$220.00
SEPT Mid Target
$230.00
SEPT High Target
$246.00
Analyst Consensus
$230.00
Is PVLA a Buy or Sell Right Now?
Thesis
- •Revenue growing 65.3% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for PVLA.
Start Free Trial →Is PVLA Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$182.37
19
Moat Score
NONE
1/9
Piotroski Score
28.3
Altman Z-Score
What Is Smart Money Doing with PVLA?
Insider Signal
SELLING
0 buys / 18 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Goin Kathleen | officer | Buy | 2,165 | $15K | Oct 21, 2026 |
| Goin Kathleen | officer | Buy | 2,148 | $20K | Oct 21, 2026 |
| Goin Kathleen | officer | Sale | 2,043 | $253K | Oct 21, 2026 |
| Goin Kathleen | officer | Sale | 1,663 | $208K | Oct 21, 2026 |
| Goin Kathleen | officer | Sale | 607 | $77K | Oct 21, 2026 |
| JENKINS GEORGE M | director | Sale | 476 | $58K | Oct 14, 2026 |
| JENKINS GEORGE M | director | Sale | 2,072 | $254K | Oct 14, 2026 |
| JENKINS GEORGE M | director | Sale | 2,604 | $321K | Oct 14, 2026 |
| JENKINS GEORGE M | director | Sale | 920 | $114K | Oct 14, 2026 |
| JENKINS GEORGE M | director | Sale | 597 | $75K | Oct 14, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →PVLA Growth Story
Revenue YoY
65.3%
3yr Revenue CAGR
N/A%
EPS Growth YoY
52.62%
FCF Growth YoY
N/A%
Revenue Trend
ACCELERATING
Dark Pool Trades for PVLA
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for PVLA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 17:14:53 | $156.35 | 1,000 | $$156K | SELL |
| 16:11:00 | $157.41 | 1,248 | $$196K | SELL |
| 21:00:34 | $163.94 | 1,062 | $$174K | SELL |
| 20:55:01 | $164.41 | 1,100 | $$181K | MIDPOINT |
| 20:55:01 | $164.41 | 1,100 | $$181K | MIDPOINT |
5 dark pool trades shown · $$889K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for PVLA
PREVIEWSEPT Investing provides real-time options flow tracking for PVLA, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $125 | May 21 | 190 | $$4352 | 1 | SWEEP |
| CALL | $165 | May 21 | 190 | $$2253 | 1 | SWEEP |
| CALL | $145 | May 21 | 190 | $$3184 | 1 | SWEEP |
| CALL | $180 | May 21 | 190 | $$1723 | 1 | SWEEP |
| CALL | $145 | May 21 | 190 | $$3180 | 1 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for PALVELLA THERAPEUTICS, INC. (PVLA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →PVLA — frequently asked questions
What is PVLA stock price today?
PALVELLA THERAPEUTICS, INC. (PVLA) is at $153.18, down 6.56% (-$10.76) at the Nov 12, 2026 close.
Why is PVLA stock moving today?
Latest PVLA news — Nov 12, 2026: Palvella Therapeutics, Inc. filed an insider trading report (Form 4) · Nov 9, 2026: Canaccord Genuity keeps Buy rating on Palvella Therapeutics, lifts price target
What is the PVLA price target?
The average analyst price target for PVLA is $230.00, ranging from $220 to $246, based on 4 analysts. Latest: HC Wainwright & Co. maintains on Oct 12, 2026.
What do analysts rate PVLA?
Analyst ratings for PVLA: 0 Buy, 5 Hold, 0 Sell — consensus Hold.
Did PVLA beat earnings?
PVLA last reported on Aug 4, 2026: EPS -$1.52 vs -$1.17 expected — a miss of 29.9%.
Does PVLA pay a dividend?
PVLA does not currently pay a dividend.
What are PVLA support and resistance levels?
Support: $141.98, $131.20, $118.22. Resistance: $156.82, $179.95, $247.20.
What are insiders doing with PVLA?
Insider activity: SELLING, 0 buys and 18 sells in the last 90 days.
What is the latest news on PVLA?
Nov 12, 2026: Palvella Therapeutics, Inc. filed an insider trading report (Form 4) · Nov 9, 2026: Canaccord Genuity keeps Buy rating on Palvella Therapeutics, lifts price target · Nov 9, 2026: Canaccord Genuity keeps Buy rating on Palvella Therapeutics, lifts target to $243